Keywords: UK, NICE, GlaxoSmithKline, Tyverb, Herceptin, Roche, Breast cancer

UK NICE says benefits of breast cancer drugs Tyverb and Herceptin still unproven

Article | 03 July 2011

Print This

In a draft guidance issued last Friday, the UK’s drug watchdog, the National Institute for Health and Clinical ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in